Patient and transplantation characteristics in 50 patients more than 55 years of age with myelodysplastic syndrome (MDS) who underwent bone marrow transplantation
| Characteristic . | No. of patients . |
|---|---|
| Gender (M/F) | 35/15 |
| FAB category at transplantation | |
| RA | 13 |
| RAEB | 19 |
| RAEB-T/AML | 16 |
| CMML | 2 |
| Cytogenetic risk* | |
| Low (1) | 24 |
| Intermediate (2) | 7 |
| High (3) | 15 |
| Unknown | 4 |
| Etiology of MDS | |
| Primary | 42 |
| Secondary | 8 |
| Conditioning regimen | |
| CY (120 mg/kg) + TBI (6 × 2 Gy) | 15 |
| CY (120 mg/kg) + TMI (4 or 5 × 2 Gy) | 4 |
| Busulfan (7 mg/kg) + TBI (6 × 2 Gy) | 4 |
| Busulfan (16 mg/kg) + CY (120 mg/kg) | 11 |
| Busulfan (targeted)† + CY (120 mg/kg) | 16 |
| GVHD prophylaxis | |
| Cyclosporine + methotrexate | 38 |
| Other | 8 |
| None | 4 |
| Marrow donor | |
| Related HLA identical | 36 |
| HLA-nonidentical | 4 |
| Syngeneic | 4 |
| Unrelated | 6 |
| Characteristic . | No. of patients . |
|---|---|
| Gender (M/F) | 35/15 |
| FAB category at transplantation | |
| RA | 13 |
| RAEB | 19 |
| RAEB-T/AML | 16 |
| CMML | 2 |
| Cytogenetic risk* | |
| Low (1) | 24 |
| Intermediate (2) | 7 |
| High (3) | 15 |
| Unknown | 4 |
| Etiology of MDS | |
| Primary | 42 |
| Secondary | 8 |
| Conditioning regimen | |
| CY (120 mg/kg) + TBI (6 × 2 Gy) | 15 |
| CY (120 mg/kg) + TMI (4 or 5 × 2 Gy) | 4 |
| Busulfan (7 mg/kg) + TBI (6 × 2 Gy) | 4 |
| Busulfan (16 mg/kg) + CY (120 mg/kg) | 11 |
| Busulfan (targeted)† + CY (120 mg/kg) | 16 |
| GVHD prophylaxis | |
| Cyclosporine + methotrexate | 38 |
| Other | 8 |
| None | 4 |
| Marrow donor | |
| Related HLA identical | 36 |
| HLA-nonidentical | 4 |
| Syngeneic | 4 |
| Unrelated | 6 |
FAB denotes French-American-British classification; RA, refractory anemia; RAEB, RA with excess blasts; RAEB-T/AML, RAEB in transformation/acute myelogenous leukemia; CMML, chronic myelomonocytic leukemia; CY, cyclophosphamide; TBI, total body irradiation; TMI, total marrow irradiation (TBI with liver and lung shielding); and GVHD, graft-versus-host disease. Median (range) age (years): 59 (55.3-66.2).
According to International Prognostic Scoring System.1
Busulfan plasma steady-state levels reached 714 to 961 ng/mL (median, 838 ng/mL; mean, 845 ng/mL).